OBJECTIVES: Recent clinical data suggest that severe kala-azar (or visceral leishmaniasis) is an exaggerated innate immune response mediated by inflammatory cytokines, leading to a systemic inflammatory syndrome similar to what is observed in malaria, sepsis and other diseases. We tested this hypothesis by measuring serum cytokines in individuals with kala-azar. METHODS: We compared patients with severe kala-azar (i.e. hemorrhagic manifestations, n = 38) with patients without evidence of hemorrhage (n = 96). We conducted a detailed clinical and laboratory evaluation, measuring serum IL-1beta, IL-6, IL-8, IL-10, IL-12, interferon-gamma, and TNF-alpha, and markers of disseminated intravascular coagulation (DIC). RESULTS: Infants had higher levels of inflammatory cytokines, while HIV-infected patients had lower concentrations of IL-10 and interferon-gamma. Higher levels of IL-6, interferon-gamma, and IL-8 were found among deceased patients. IL-8 and interferon-gamma were independently associated with bleeding. Several cytokines were associated with different signs of severe clinical and laboratory manifestations, including DIC. IL-6 was highly positively and independently associated with IL-1beta, IL-8, IL-10, and negatively associated with TNF-alpha. IL-1beta and TNF-alpha were also highly independently associated with disease severity. CONCLUSION: In its severe form, kala-azar, a neglected tropical disease, initiates a systemic inflammatory response that leads to DIC and other manifestations. Children may have higher risk of death due to the more intense cytokine release. The data supports the notion that IL-6 is the central cytokine that is associated with lethal disease, but interferon-gamma, IL1beta, IL-8, and TNF-alpha are also involved with disease severity. Inhibition of IL-6 is a potential target of adjuvant therapy for severe or pediatric forms of this disease.
OBJECTIVES: Recent clinical data suggest that severe kala-azar (or visceral leishmaniasis) is an exaggerated innate immune response mediated by inflammatory cytokines, leading to a systemic inflammatory syndrome similar to what is observed in malaria, sepsis and other diseases. We tested this hypothesis by measuring serum cytokines in individuals with kala-azar. METHODS: We compared patients with severe kala-azar (i.e. hemorrhagic manifestations, n = 38) with patients without evidence of hemorrhage (n = 96). We conducted a detailed clinical and laboratory evaluation, measuring serum IL-1beta, IL-6, IL-8, IL-10, IL-12, interferon-gamma, and TNF-alpha, and markers of disseminated intravascular coagulation (DIC). RESULTS:Infants had higher levels of inflammatory cytokines, while HIV-infectedpatients had lower concentrations of IL-10 and interferon-gamma. Higher levels of IL-6, interferon-gamma, and IL-8 were found among deceased patients. IL-8 and interferon-gamma were independently associated with bleeding. Several cytokines were associated with different signs of severe clinical and laboratory manifestations, including DIC. IL-6 was highly positively and independently associated with IL-1beta, IL-8, IL-10, and negatively associated with TNF-alpha. IL-1beta and TNF-alpha were also highly independently associated with disease severity. CONCLUSION: In its severe form, kala-azar, a neglected tropical disease, initiates a systemic inflammatory response that leads to DIC and other manifestations. Children may have higher risk of death due to the more intense cytokine release. The data supports the notion that IL-6 is the central cytokine that is associated with lethal disease, but interferon-gamma, IL1beta, IL-8, and TNF-alpha are also involved with disease severity. Inhibition of IL-6 is a potential target of adjuvant therapy for severe or pediatric forms of this disease.
Authors: Pio Conti; Duraisamy Kempuraj; Kristiana Kandere; Mario Di Gioacchino; Renato C Barbacane; Maria L Castellani; Mario Felaco; William Boucher; Richard Letourneau; Theoharis C Theoharides Journal: Immunol Lett Date: 2003-04-03 Impact factor: 3.685
Authors: Elizabeta Nemeth; Erika V Valore; Mary Territo; Gary Schiller; Alan Lichtenstein; Tomas Ganz Journal: Blood Date: 2002-11-14 Impact factor: 22.113
Authors: Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo Journal: Antimicrob Agents Chemother Date: 2014-11-03 Impact factor: 5.191
Authors: Thais Alves da Costa-Silva; Simone S Grecco; Fernanda S de Sousa; João Henrique G Lago; Euder G A Martins; César A Terrazas; Sanjay Varikuti; Katherine L Owens; Stephen M Beverley; Abhay R Satoskar; Andre G Tempone Journal: J Nat Prod Date: 2015-04-02 Impact factor: 4.050
Authors: Joyce M Silva; Danielle A Zacarias; Lívio C de Figueirêdo; Maria Regiane A Soares; Edna A Y Ishikawa; Dorcas L Costa; Carlos H N Costa Journal: Am J Trop Med Hyg Date: 2014-03-10 Impact factor: 2.345
Authors: Vera Lucia Lanchote; Roque Almeida; Aldina Barral; Manoel Barral-Netto; Maria Paula Marques; Natália V Moraes; Angela M da Silva; Tania M V Souza; Guilherme Suarez-Kurtz Journal: Br J Clin Pharmacol Date: 2015-07-02 Impact factor: 4.335
Authors: Diego Lins Guedes; Elis Dionísio da Silva; Maria Carolina Accioly Brelaz Castro; Walter Lins Barbosa Júnior; Ana Victoria Ibarra-Meneses; Achilleas Tsoumanis; Wim Adriaensen; Johan van Griensven; Valéria Rêgo Alves Pereira; Zulma Maria de Medeiros Journal: PLoS Negl Trop Dis Date: 2022-06-17
Authors: Priscila L Dos Santos; Fabrícia A de Oliveira; Micheli Luize B Santos; Luana Celina S Cunha; Michelle T B Lino; Michelle F S de Oliveira; Manuela O M Bomfim; Angela Maria Silva; Tatiana R de Moura; Amélia R de Jesus; Malcolm S Duthie; Steven G Reed; Roque P de Almeida Journal: PLoS Negl Trop Dis Date: 2016-01-27
Authors: Melanie Charmoy; Benjamin P Hurrell; Audrey Romano; Sang Hun Lee; Flavia Ribeiro-Gomes; Nicolas Riteau; Katrin Mayer-Barber; Fabienne Tacchini-Cottier; David L Sacks Journal: Eur J Immunol Date: 2016-01-20 Impact factor: 5.532
Authors: Sania Aslam; Waqas Younis; Muhammad Nasir Hayat Malik; Shah Jahan; Ambreen Malik Uttra; Muhammad Usman Munir; Muhammad Roman Journal: Inflammopharmacology Date: 2022-03-23 Impact factor: 4.473